Associated Genetic Biomarkers
Signal transducer and activator of transcription 5B (STAT5B) is a gene that encodes a protein that functions as a transcription activator. Missense mutations, nonsense mutations, silent mutations, and frameshift deletions and insertions are observed in cancers such as intestinal cancer, skin cancer, and stomach cancer.
STAT5B is altered in 0.83% of all cancers with colon adenocarcinoma, lung adenocarcinoma, endometrial endometrioid adenocarcinoma, prostate adenocarcinoma, and breast invasive ductal carcinoma having the greatest prevalence of alterations .
The most common alterations in STAT5B are STAT5B Mutation (0.65%), STAT5B Amplification (0.10%), STAT5B Loss (0.07%), STAT5B N642H (0.45%), and STAT5B T628S (0.19%) .
STAT5B status serves as an inclusion eligibility criteria in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial that contains STAT5B status as an inclusion criterion, 1 is phase 2 (0 open).
Trials with STAT5B status in the inclusion eligibility criteria most commonly target malignant solid tumor .
The most frequent alterations to serve as inclusion eligibility criteria are STAT5B Loss and STAT5B Mutation .
Irinotecan and sorafenib are the most frequent therapies in trials with STAT5B as an inclusion criteria .
Significance of STAT5B in Diseases
Malignant Solid Tumor +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.